Pembrolizumab plus axitinib for metastatic papillary and chromophobe renal cell carcinoma: nemesia (non clear metastatic renal cell carcinoma pembrolizumab axitinib) study, a subgroup analysis of i-rare observational study (meet-uro 23a)

HIGHLIGHTS

• who: Marco Stellato et al. from the , Milano, Italy Department of Medicine and Surgery, University of Parma, Parma, Italy have published the paper: Pembrolizumab Plus Axitinib for Metastatic Papillary and Chromophobe Renal Cell Carcinoma: NEMESIA (Non Clear MEtaStatic Renal Cell Carcinoma Pembrolizumab Axitinib) Study, a Subgroup Analysis of I-RARE Observational Study (Meet-URO 23a), in the Journal: (JOURNAL)
• what: The aim of this study was to investigate the effectiveness and tolerability of pembrolizumabaxitinib combination in chromophobe and RCC (mRCC) patients enrolled in the I-RARE (Italian Registry on rAre genitor-uRinary nEoplasms) observational ongoing . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or E-mail:

  If you don't have an account, you can create one here.